source
- Pharma faces $500B risk as patents expire, with Merck most exposed by 2028More than $500 billion in global prescription sales could be threatened by generic competition between 2026 and 2032, according to Norstella data cited by Evaluate. Merck is the most immediately e…
- Aspen Neuroscience files for Nasdaq IPO to fund Parkinson’s cell therapy programAspen Neuroscience, founded in 2018, announced plans to list on Nasdaq, aiming to raise additional capital for its Parkinson’s disease cell therapy program. The company's lead candidate, sasinepro…